SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

IDVYNSO

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already launched and on the market. FDA approved April 21, 2026, and the drug became available in U.S. pharmacies after May 11, 2026.
Why 4/10
IDVYNSO was approved by the FDA in April 2026 and is now a commercial-stage drug. There is no pending PDUFA date, pivotal readout, or advisory-committee decision scheduled for the next ~12 months. The next catalyst is the Q4 2026/full-year earnings report (early 2027) for the first full launch-year sales data, but quarterly commercial updates are not hard binary catalysts. As a recently launched product within Merck's large, diversified portfolio, IDVYNSO's impact on MRK share price is moderate and gradual rather than a single binary event.
Actionable Insight NEUTRAL

IDVYNSO is now a commercial-stage launch product for Merck. The next catalyst to watch is Merck's Q4 2026 / full-year earnings (expected late January/early February 2027) for the first meaningful IDVYNSO sales trajectory data since its May 2026 U.S. launch. Consensus estimates call for $220M-$280M in 2026 launch-year sales. Any quarterly print meaningfully above or below that range could move sentiment on MRK modestly, but IDVYNSO is one of many growth drivers in Merck's diversified portfolio and is unlikely to drive a binary move on its own.

Price Chart

Loading chart...

Executive Summary

IDVYNSO is Merck & Co.'s (NYSE: MRK) newly approved fixed-dose combination of doravirine and islatravir for HIV-1, approved by the FDA on April 21, 2026. It is the first and only once-daily, non-INSTI (integrase strand transfer inhibitor), tenofovir-free two-drug regimen for virologically suppressed adults. Phase 3 trials showed non-inferior efficacy head-to-head against Gilead's three-drug blockbuster Biktarvy. IDVYNSO is now a commercial-stage launch product for Merck, included among the company's roster of new launches alongside Winrevair, Capvaxive, and others. Consensus analyst estimates project launch-year 2026 sales of $220M-$280M, rising to ~$950M in 2027, with peak sales of ~$1.1B by 2030. Merck aims to position IDVYNSO as its new HIV anchor therapy. However, the drug enters a highly competitive market led by Gilead and ViiV Healthcare, and its indication is restricted to switch therapy in suppressed patients. For Merck, a $140B+ market-cap diversified pharma with many larger products (Keytruda ~$30B+ annually, Gardasil, Winrevair), IDVYNSO is a meaningful growth contributor but not a make-or-break asset, and its approval binary has already passed.

How It Works

IDVYNSO is a once-daily, two-drug combination pill for HIV-1. It contains doravirine (a non-nucleoside reverse transcriptase inhibitor or NNRTI) and islatravir (a nucleoside reverse transcriptase inhibitor or NRTI). Both drugs stop HIV from replicating by blocking an enzyme called reverse transcriptase that the virus needs to multiply. Because the two drugs attack the same enzyme through different mechanisms, the combination is effective as a complete standalone regimen without needing a third drug.

Trial Status

IDVYNSO was approved by the FDA on April 21, 2026 based on positive 48-week data from three pivotal Phase 3 trials (NCT05705349 and others) that demonstrated non-inferior efficacy and comparable safety versus three-drug regimens including Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and other standard oral antiretroviral therapies. Results were presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) and published in The Lancet.

The Two-Sided Case

▲ Bull Case5
IDVYNSO is the first and only FDA-approved non-INSTI, tenofovir-free, once-daily two-drug HIV regimen, giving it a unique positioning for patients who need to avoid integrase inhibitors or tenofovir.
Phase 3 data demonstrated non-inferior efficacy head-to-head against Gilead's market-leading three-drug regimen Biktarvy, a high bar that supports a strong clinical profile.
Consensus estimates project launch-year 2026 sales of $220M-$280M rising to ~$950M in 2027, with peak sales of ~$1.1B by 2030, adding a meaningful new growth leg for Merck.
NCE-1 exclusivity runs through April 2030, providing several years of market protection before generic competition.
Merck's existing infectious-disease sales force and ADAP access programs position IDVYNSO for rapid formulary penetration.
▼ Bear Case4
IDVYNSO enters a fiercely competitive HIV market dominated by Gilead's Biktarvy and ViiV Healthcare's Dovato, making market share gains difficult.
The drug is limited to virologically suppressed adults with no history of treatment failure or doravirine resistance, narrowing its addressable patient pool.
As a small molecule oral HIV drug in a crowded field, IDVYNSO faces significant pricing and payer-access headwinds.
Islatravir was previously placed on clinical hold by the FDA in prior development programs due to safety concerns (lymphocyte declines at higher doses), and any future safety signal could impact perception of the combination.

Upcoming Catalysts

  • Q4 2026 / full-year 2026 earnings report (expected late January / early February 2027), which will provide the first full-year sales data for IDVYNSO since its May 2026 launch and indicate whether the drug is tracking toward consensus estimates of $220M-$280M.
  • Expansion into international markets: regulatory filings and launches outside the U.S. (EU, GCC, and other regions) over the coming 12-24 months.
  • Potential label expansion studies for islatravir-based combinations, including ongoing development of a once-weekly oral regimen combining islatravir with lenacapavir (in collaboration with Gilead).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 12

Hover a chip for the title
1 merck.com2 merck.com3 idvynso.com4 drugs.com5 merck.com6 insights.citeline.com7 biospace.com8 bvwd.ca.gov9 bionixus.com10 fiercepharma.com11 drugs.com12 merckconnect.com